These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10370188)

  • 1. Development of a membrane-controlled transdermal therapeutic system containing isosorbide dinitrate.
    Ocak F; Ağabeyoğlu I
    Int J Pharm; 1999 Apr; 180(2):177-83. PubMed ID: 10370188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membrane permeation-controlled transdermal delivery system design. Influence of controlling membrane and adhesive on skin permeation of isosorbide dinitrate.
    Seki T; Kawaguchi T; Sugibayashi K; Juni K; Morimoto Y
    Chem Pharm Bull (Tokyo); 1990 Mar; 38(3):740-3. PubMed ID: 2347017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies on transdermal delivery system of isosorbide dinitrate].
    Ji AM; Jiang XT; Wang XF; Zou HQ
    Yao Xue Xue Bao; 1992; 27(11):858-63. PubMed ID: 1300032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal delivery of isosorbide 5-mononitrate from a new membrane reservoir and matrix-type patches.
    Arra GS; Arutla S; Krishna DR
    Drug Dev Ind Pharm; 1998 May; 24(5):489-92. PubMed ID: 9876613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization.
    Zhao JH; Fu JH; Wang SM; Su CH; Shan Y; Kong SJ; Wang Y; Lu WL; Zhang H; Zhang S; Li L; Zhang EH; Wang L; Pei QL; Wang JC; Zhang X; Zhang Q
    Int J Pharm; 2007 Jun; 337(1-2):88-101. PubMed ID: 17267147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system.
    Gabiga H; Cal K; Janicki S
    Int J Pharm; 2000 Apr; 199(1):1-6. PubMed ID: 10794921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the transdermal delivery of nimodipine from a menthol-based TTS in human volunteers.
    Krishnaiah YS; Bhaskar P
    Curr Drug Deliv; 2004 Apr; 1(2):93-102. PubMed ID: 16305374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limonene enhances the in vitro and in vivo permeation of trimetazidine across a membrane-controlled transdermal therapeutic system.
    Krishnaiah YS; Al-Saidan SM
    Curr Drug Deliv; 2008 Jan; 5(1):70-6. PubMed ID: 18220554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electron beam irradiation: a novel technology for the development of transdermal system of isosorbide dinitrate.
    Kotiyan PN; Vavia PR; Bhardwaj YK; Sabarwal S; Majali AB
    Int J Pharm; 2004 Feb; 270(1-2):47-54. PubMed ID: 14726121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization and in vitro drug release of isosorbide dinitrate microspheres.
    Dinarvand R; Mirfattahi S; Atyabi F
    J Microencapsul; 2002; 19(1):73-81. PubMed ID: 11811761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of isosorbide dinitrate concentration on its skin permeability from adhesive matrix devices.
    Hatanaka T; Oguchi M; Sugibayashi K; Morimoto Y
    Chem Pharm Bull (Tokyo); 1991 Jul; 39(7):1802-5. PubMed ID: 1777935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of vehicles and pressure sensitive adhesives on the penetration of isosorbide dinitrate across the hairless mouse skin.
    Myoung Y; Choi HK
    Drug Deliv; 2002; 9(2):121-6. PubMed ID: 12055040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and evaluation of limonene-based membrane-moderated transdermal therapeutic system of nimodipine.
    Krishnaiah YS; Bhaskar P; Satyanarayana V
    Drug Deliv; 2004; 11(1):1-9. PubMed ID: 15168785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous pharmacodynamics of transdermally delivered isosorbide dinitrate.
    Hori M; Ohtsuka S; Sunami M; Guy RH; Maibach HI
    Pharm Res; 1990 Dec; 7(12):1298-301. PubMed ID: 2095569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
    Kogi K; Tanaka O; Kimura T; Saito T
    Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
    Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
    Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and control-release kinetics of isosorbide dinitrate microspheres.
    Yang GM; Kuo JF; Woo EM
    J Microencapsul; 2006 Sep; 23(6):622-31. PubMed ID: 17118878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled release of triprolidine using ethylene-vinyl acetate membrane and matrix systems.
    Shin SC; Lee HJ
    Eur J Pharm Biopharm; 2002 Sep; 54(2):201-6. PubMed ID: 12191692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
    Sata H; Inoue K; Nii T; Kuroda T
    Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.